Streptomycin, an antibiotic substance obtained from the microorganism Actinomyces griseus, was described in January 1944 by Schatz, Bugie and Waksman.1 This material was shown to possess activity in vitro over a wide range of bacteria but was of particular interest because it was effective against many bacteria which were not susceptible to the chemotherapeutic substances then available for the treatment of human infections. Subsequent reports have confirmed these observations and, in addition, have shown that streptomycin is effective in the treatment of experimental infections with organisms of the Eberthella and Salmonella groups2 and with Pseudomonas aeruginosa, Shigella gallinarum, Brucella abortus and Proteus vulgaris,3 as well as with Pasteurella tularensis4 and with the Klebsiella organisms.5 Streptomycin was also found to possess activity against the tubercle bacillus both in vitro6 and in vivo.7 The toxicity of a partially purified product for mice was reported to be of a fairly low order
ADCOCK JD, HETTIG RA. ABSORPTION, DISTRIBUTION AND EXCRETION OF STREPTOMYCIN. Arch Intern Med (Chic). 1946;77(2):179–195. doi:10.1001/archinte.1946.00210370060005
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.